Clinical Trials

  

Study of Subretinal Implantation of Human Embryonic Stem Cell-Derived RPE Cells in Advanced Dry AMD


The Phase I/IIa clinical trial is designed to assess the feasibility of delivery and safety of Human Embryonic Stem Cell-Derived RPE Cells on a parylene membrane (CPCB-RPE1) in patients with advanced, dry age-related macular degeneration.



Primary Objective:  To test the safety and tolerability of CPCB-RPE1 during and after subretinal implantation in patients with geographic atrophy with evidence of involvement of the central fovea.



Secondary Objective: To assess visual acuity, visual field, and retinal function after CPCB-RPE1 implantation. Implanted and fellow eyes will be compared post-implantation to assess the ability of the implant to prevent disease progression.




Who can participate?

Females and Males diagnosed with advanced Dry Age-related Macular Degeneration

Ages 55-85 years 

Severe vision loss due to Dry AMD in at least one of the eyes 

Willing to have a surgical procedure to replace damage and lost cells in the retina 

Willing to undergo diagnostic testing after surgery to monitor the response of the retina 



This trial is registered at clinicaltrials.gov Click here to learn more about Study Locations and Eligibility